The trajectory of the erectile dysfunction drug presents a intricate picture for those considering investment. While the initial release generated substantial returns, the end of its intellectual property protection https://bookmarkingdelta.com/story21600696/sildenafil-and-the-pharmaceutical-industry-a-risky-bet